These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1927963)

  • 1. Sudden death due to ventricular tachycardia during amiodarone therapy in familial hypertrophic cardiomyopathy.
    Gilligan DM; Missouris CG; Boyd MJ; Oakley CM
    Am J Cardiol; 1991 Oct; 68(9):971-3. PubMed ID: 1927963
    [No Abstract]   [Full Text] [Related]  

  • 2. Failure of amiodarone to prevent ventricular fibrillation (sudden death) in hypertrophic cardiomyopathy.
    Mercereau D; Kubac G; Klinke WP
    Can J Cardiol; 1989 Mar; 5(2):77-80. PubMed ID: 2706577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Arrhythmias in hypertrophic cardiomyopathy. Significance and therapeutic consequences].
    McKenna WJ; Kleinebenne A
    Herz; 1985 Apr; 10(2):91-101. PubMed ID: 2580767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death.
    Buja G; Miorelli M; Turrini P; Melacini P; Nava A
    Am J Cardiol; 1993 Oct; 72(12):973-6. PubMed ID: 8213559
    [No Abstract]   [Full Text] [Related]  

  • 5. Sustained arrhythmias in hypertrophic obstructive cardiomyopathy.
    Kowey PR; Eisenberg R; Engel TR
    N Engl J Med; 1984 Jun; 310(24):1566-9. PubMed ID: 6539421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arrhythmia and prognosis in hypertrophic cardiomyopathy.
    McKenna WJ
    Eur Heart J; 1983 Nov; 4 Suppl F():225-34. PubMed ID: 6686539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy.
    Fananapazir L; Leon MB; Bonow RO; Tracy CM; Cannon RO; Epstein SE
    Am J Cardiol; 1991 Jan; 67(2):169-74. PubMed ID: 1987718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arrhythmia and hypertrophic cardiomyopathy.
    Shakespeare CF; Keeling PJ; Slade AK; McKenna WJ
    Arch Mal Coeur Vaiss; 1992 Dec; 85 Spec No 4():31-6. PubMed ID: 1307192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of arrhythmias in hypertrophic cardiomyopathy].
    Rapezzi C; Spirito P
    G Ital Cardiol; 1995 Nov; 25(11):1443-6. PubMed ID: 8682242
    [No Abstract]   [Full Text] [Related]  

  • 10. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy.
    McKenna WJ; Harris L; Rowland E; Kleinebenne A; Krikler DM; Oakley CM; Goodwin JF
    Am J Cardiol; 1984 Oct; 54(7):802-10. PubMed ID: 6541429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of electrophysiologic studies in hypertrophic cardiomyopathy treated with amiodarone.
    Fananapazir L; Epstein SE
    Am J Cardiol; 1991 Jan; 67(2):175-82. PubMed ID: 1987719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inducible polymorphic ventricular tachycardia and ventricular fibrillation in a subgroup of patients with hypertrophic cardiomyopathy at high risk for sudden death.
    Watson RM; Schwartz JL; Maron BJ; Tucker E; Rosing DR; Josephson ME
    J Am Coll Cardiol; 1987 Oct; 10(4):761-74. PubMed ID: 3655144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population.
    Cecchi F; Olivotto I; Montereggi A; Squillatini G; Dolara A; Maron BJ
    Heart; 1998 Apr; 79(4):331-6. PubMed ID: 9616338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: risk stratification based on clinical variables.
    DiCarlo LA; Morady F; Sauve MJ; Malone P; Davis JC; Evans-Bell T; Winston SA; Scheinman MM
    Am J Cardiol; 1985 Feb; 55(4):372-4. PubMed ID: 3969871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influence of atrial fibrillation in the natural history of hypertrophic cardiomyopathy].
    Albanesi Filho FM; Girardi JM; Castier MB; Ginefra P
    Arq Bras Cardiol; 1994 May; 62(5):337-41. PubMed ID: 7998866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia.
    McKenna WJ; Oakley CM; Krikler DM; Goodwin JF
    Br Heart J; 1985 Apr; 53(4):412-6. PubMed ID: 4039188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed electrical stimulation in hypertrophic cardiomyopathy. Results in patients with and without cardiac arrest or syncope.
    Kuck KH; Kunze KP; Schlüter M; Nienaber CA; Costard A
    Eur Heart J; 1988 Feb; 9(2):177-85. PubMed ID: 3280318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ambulatory ECG in cardiomyopathies].
    Mestroni L; Miani D; Neri R; Di Lenarda A; Camerini F
    G Ital Cardiol; 1987 Dec; 17(12):1139-44. PubMed ID: 3503812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of a serial electropharmacologic study in survivors of a cardiac arrest secondary to ventricular tachycardia or ventricular fibrillation].
    Raviele A; Di Pede F; Delise P; Piccolo E
    G Ital Cardiol; 1984 Sep; 14(9):644-54. PubMed ID: 6510619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supraventricular arrhythmia as the cause of sudden death in hypertrophic cardiomyopathy.
    Madariaga I; Carmona JR; Mateas FR; Lezaun R; de los Arcos E
    Eur Heart J; 1994 Jan; 15(1):134-7. PubMed ID: 8174574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.